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Abstract
The purpose of this study was to determine whether there is an increased risk of suicide in European Hodgkin Lymphoma (HL)
patients compared to the general European population.
European HL patients enrolled in the German Hodgkin Study Group (GHSG) HD7 through HD15 studies were analyzed and
standardized mortality ratio (SMR) was calculated using suicide mortality rates for the general European population. Case-control
analysis was performed to identify characteristics associated with risk of death by suicide. Among 12,202 European HL patients
observed for 94,972 person-years, 19 suicides (17 males and 2 females) were identiﬁed resulting in a SMR 1.63 (95% CI: 1.01–2.50,
p=0.046). The only characteristic associated with a statistically signiﬁcant increased risk of suicide was male sex with an odds ratio
(OR) 8.42 (95% CI=1.04–67.85; p=0.046) on multivariate analysis. These ﬁndings were conﬁrmed in an independently analyzed
Surveillance, Epidemiology, and End Results Program (SEER) validation dataset. European HL patients have a signiﬁcantly increased
incidence of suicide compared to the general European population. Male HL patients have a greater than 8-fold increased risk of
suicide compared to female HL patients. Further study of social risk factors associated with an increased risk of suicide in HL patients
is needed.
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Introduction
A retrospective population study in the United States using the
Surveillance, Epidemiology, and End Results Program (SEER)
database compared suicide rates by anatomic cancer site and
found a statistically signiﬁcant standardized mortality ratio
(SMR) of 2.07 in Hodgkin Lymphoma (HL) patients compared
to the general US population.1 This study was not speciﬁc to HL,
nor did it look at clinical information related to HL. The largest
clinical trials in HL have been performed in Europe, and suicide
has not been studied in this population. To determine if there is an
increase in suicide incidence in European HL patients compared
to the general European population, we analyzed data from
several randomized European HL clinical trials. We sought to
identify demographic, disease, and treatment-speciﬁc character-
istics in HL patients associated with an increased risk of suicide.
We also attempted to validate our ﬁndings by an independent
review of SEER registry data for HL patients and suicide.
Results
Nineteen patients (17 males and 2 females) died by suicide in the
GHSGHD7-HD15 studies. Demographic, disease, and treatment
information of the entire cohort and the 19 patients with death by
suicide is included in Table 1. Suicide was the seventh most
common cause of death, making up 1.6% of all deaths, in the
analyzed cohort of HL patients (Fig. 1). Median follow-up time
was 85 months, total observation time was 94,972 person-years,
and the crude suicide rate of HL patients was 20.01/100,000
person-years. The corresponding expected suicide rate in the
general European population was 12.29/100,000 person-years
(Eurostat).16 SMR for the entire HL cohort was 1.63 (95% CI:
1.01–2.50) that was signiﬁcantly elevated (p<0.05) with p=
0.046. The crude suicide rate of male HL patients was 32.29/
100,000 person-years, and the corresponding expected suicide
rate in the general male European population was 19.85/100,000
person-years with a SMR of 1.63 (95% CI: 0.98–2.55) that was
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not signiﬁcantly different from 1 likely due to a smaller sample
size (p=0.059). Female HL patients did not have an increased
suicide rate compared to the general female European population
(SMR 0.95, 95%-CI: 0.16–3.13, p=0.940). We conﬁrmed these
ﬁndings in the independent SEER dataset, with 105 suicides in a
total observation time of 483,264 person-years. The crude
incidence in the SEER data was 21.73/100,000 person-years. The
corresponding expected suicide rate in the U.S. population was
13.46/100,000 person-years, resulting in a SMR of 1.56 (95%
CI: 1.29–1.89) that was signiﬁcantly different from 1 (p<0.001)
and remarkably similar to the SMR obtained in the European
population. We also conﬁrmed the elevated suicide rate in male
HL patients (SMR: 1.57, 95%-CI: 1.27–1.92, p<0.001) and the
non-elevated suicide rate in female HL patients (SMR: 1.15,
95%-CI: 0.66–1.89, p=0.58) in the SEER validation dataset.
Suicide risk over time
The highest risk of suicide was during the ﬁrst year after diagnosis
of HL (Fig. 2). Median time to suicide of patients diagnosed with
HL between ages 15–49 was 56 months (95% CI: 36–91), and
only 13 months (95% CI: 1–34) for patients diagnosed between
ages 50–59 (Fig. 3). The highest risk of suicide in both male and
female HL patients was between ages 50–59.Male HL patients of
most age groups had increased suicide risk, reaching statistical
signiﬁcance in the group of 40–49-year-olds. In females, risk of
suicide was only increased in those aged 50–59 years (Table 2).
These ﬁndings were conﬁrmed in the independent SEER dataset.
The median time to suicide of patients ages 15–49 was 98months
(95% CI: 72–122) and 49 months (95% CI: 6–93) for patients
ages 50–59 and thus similarly shorter. Patients between ages 50–
59 and male HL patients age 40–49 in the validation cohort had
SMRs of 1.63 (95%-CI: 0.83–2.91, p=0.14) and 1.63 (95%-CI:
0.93–2.68, p=0.08), respectively.
Case-control analysis
Nineteen patients with death by suicide (cases) were matched
with 57 controls. The results of the univariate analysis are
summarized in Table 3.Male sex was the only variable associated
with a statistically signiﬁcant increased risk of suicide, odds ratio
(OR) 9.37 (95% CI: 1.12–75.2; p=0.035). Male sex remained
statistically signiﬁcant on multivariable conditional logistic
regression adjusting for stage (stage IV vs stage I-III) and
presence of large mediastinal mass, OR 8.49 (95% CI: 1.06–
68.22; p=0.044). We validated this ﬁnding in the SEER dataset
with a multivariable conditional logistic regression controlling
for stage (data on mediastinal mass is not available as part of the
Table 1
Patient characteristics
Death by suicide N=19; (n (%)) Total study cohort N=12,202; (n (%))
Median age at diagnosis (years) 38 (range 19–59) 36 (range 16–75)
Median time to suicide (months) 42 (range 1–142) N/A
Median age at suicide (years) 46 (range 22–59) N/A
Study generation, Time of initial diagnosis
HD7–9, 02/1993–03/1998 4 (21%) 2887 (24%)
HD10–12, 05/1998–01/2003 7 (37%) 4159 (34%)
HD13–15, 01/2003–09/2009 8 (42%) 5156 (42%)
Sex
Male 17 (89%) 6899 (57%)
Female 2 (11%) 5303 (43%)
Stage of Disease
Early stage favorable 6 (32%) 3319 (27%)
Early stage unfavorable 5 (26%) 3987 (33%)
Advanced Stage 8 (42%) 4896 (40%)
Histological subtype
Nodular sclerosis 11 (58%) 5968 (49%)
Mixed cellularity 5 (26%) 2753 (23%)
Other Classical HL 1 (5%) 840 (7%)
NLPHL 0 461 (4%)
Not Available 2 (11%) 2180 (18%)
Chemotherapy Regimen
ABVD-based 12 (63%) 5801 (48%)
BEACOPP-based 7 (37%) 6090 (50%)
Radiotherapy alone 0 311 (3%)
Secondary Malignancy
Solid Tumor 1 (5%) 488 (4%)
NHL 0 180 (1%)
Leukemia/MDS 0 108 (1%)
Radiation Therapy + Median Dose 12 (63%) + 30 Gy 8952 (73%) + 30 Gy
Relapsed Disease 2 (11%) 1256 (10%)
ABVD=doxorubicin, bleomycin, vinblastine, dacarbazine, BEACOPP=bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, Gy=Gray, MDS=Myelodysplastic Syndrome,
NHL=non-Hodgkin Lymphoma, NLPHL=Nodular Lymphocyte Predominant Hodgkin Lymphoma.
∗German Hodgkin Study Group (GHSG) risk classiﬁcation: -Early stage favorable=Stage IA, IIA, IIA, or IIB cHL, without risk factors: large mediastinal mass, extranodal disease, three or more involved lymph node
areas, or elevated ESR (≥ 50 for stages IA and IIA and≥ 30 for stages IB and IIB): -Early stage unfavorable=Stage IA, IB, or IIA with one or more above risk factors. Stage IIB only if risk factors of elevated ESR and/
or involvement of 3 or more lymph node areas are present -Advanced stage=Stage IIB with risk factors of extranodal involvement and/or large mediastinal mass. Stage IIIA, IIIB, IVA, or IVB.
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SEER data) and conﬁrmed the increased suicide risk for male
compared to female HL patients OR 5.86 (95%-CI: 2.62–13.10,
p<0.001).
Discussion
European HL patients from the GHSG HD7-HD15 clinical trials
had a signiﬁcantly increased risk of suicide, SMR 1.63, compared
to the general European population. The only variable found on
both univariate and multivariate analysis to be associated with a
statistically signiﬁcant increased risk of suicide inHL patients was
male sex. We did not ﬁnd an increased risk of suicide in HL
patients with relapsed disease, more intensive treatment
regimens, or development of secondary malignancy. Male sex
was found to confer a greater than 8-time risk of suicide in our
study of HL patients by multivariate analysis. In the general
population, males are nearly 3 to 4 times more likely than females
to commit suicide, although females are twice as likely as men to
experience major depression during their lifetime.18 This
increased risk of suicide, especially in male HL patients, was
conﬁrmed in an independent validated SEER dataset of HL
patients from the United States.
Our data suggest that the highest risk of suicide for HL patients
is within the ﬁrst 3 months and the ﬁrst year after diagnosis of
HL. This is consistent with the study by Fang et al,19 who
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reported in a Swedish population study that the relative risk (RR)
of suicide in the ﬁrst 3 months after a cancer diagnosis was 4.8
(95% CI: 4.0–5.8) and 3.1 (95% CI: 2.7–3.5) in the ﬁrst year
after a cancer diagnosis. Kwak et al reported the highest levels of
distress in adolescent and young adult survivors of cancer to be at
time of diagnosis and at 12 months, considered to be the time of
transition to survivorship.20
To our knowledge, this is the ﬁrst study looking speciﬁcally at
Hodgkin Lymphoma patients and the risk of suicide. Our study
analyzed HL clinical trial patients, and thus we were able to
evaluate the effects of demographic, disease, treatment, and
treatment complication information on the risk of suicide in HL
patients. The suicides were distributed nearly exactly among the
different study generations as the total cohort of HL patients
(Table 1). Thus, the suicide rates in the different trial generations
were very similar and stable over time. Stable suicide rates were
also seen over time in the SEER validation cohort. The major
strength of our study is the large cohort of over 12,000 European
HL patients with long term median follow-up of over 7 years and
nearly 95,000 person-years of observation time. Due to the long
follow-up and observation time, the frequency of deaths from
suicide was reliably able to be compared to other more well-
established and well-studied causes of death in HL patients.
The limitations to our study include the retrospective design
and the clinical trial data focusing on HL-speciﬁc outcome
measures that did not allow for the investigation of relevant
comorbidities such as depression and other psychiatric illnesses
such as alcohol or drug-related disorders. Aside from age and
gender, demographic information such as marital status, race,
and employment status, all relevant risk factors for suicide, were
not available. Suicides were recorded only if the patient’s treating
physician in charge of follow up reported suicide as the cause of
death, so there is the possibility of an underestimation of deaths
due to suicide but unlikely to be an overestimation. These results
are limited to European HL patients ages 16 to 75 at time of ﬁrst
HL diagnosis and would need to be validated and reproduced in
other parts of the world.
In conclusion, our study shows an increased risk of suicide in
European HL patients compared to the general European
population. The only risk factor associated with an increased
risk of suicide in European HL patients was male sex that
conferred a greater than 8 times the risk of suicide. These ﬁndings
were conﬁrmed in an independent validated SEER dataset. Of
note, the only death reported in the recent CALGB 50604 trials of
risk-adapted treatment of nonbulky early-stage HL was by
suicide in an interim PET positive patient.21 Further studies of
social risk factors are needed in addition to the disease, treatment,
and treatment complication factors analyzed here to obtain a
better understanding of suicide in HL patients. In the meantime,
an understanding by clinicians that male HL patients have a
signiﬁcantly higher risk of suicide compared to the general
population may allow these patients to obtain earlier and
increased access to emotional and social support systems. This
understanding, considering the high-risk window of 12 months
from diagnosis, may also help to inform that the optimal timing
to assess for depression and suicidality may be during and
immediately after the end of treatment.
Materials and methods
This study was approved by the University of Massachusetts
Medical School institutional review board (Certiﬁcate of
Exemption No. H00011362) and included 12,202 patients
between the ages of 16 to 75 enrolled in the German Hodgkin
Table 3
Univariate analyses of characteristics associated with suicide in HL patients
Characteristic
Frequency among suicide
cases, N=19 (N (%))
Frequency among controls,
N=57 (N (%)) OR 95% CI p
Sex (Male vs Female) 17 (89%) 34 (60%) 9.37 1.12–75.20 0.04
B symptoms 5 (26%) 21 (37%) 0.47 0.11–2.01 0.31
Elevated ESR 8 (42%) 22 (39%) 1.20 0.36–3.99 0.76
Large Mediastinal Mass 1 (5%) 9 (16%) 0.32 0.04–2.58 0.28
≥ 3 Nodal Areas 9 (47%) 31 (54%) 0.65 0.19–2.30 0.51
Stage IV vs Stage I-III 5 (26%) 8 (14%) 4.38 0.50–38.04 0.18
Radiation Therapy 12 (63%) 39 (68%) 0.39 0.04–4.39 0.45
BEACOPP vs ABVD Chemotherapy 7 (37%) 28/56 (50%)
∗
0.63 0.22–1.84 0.40
Secondary Malignancy 1 (5%) 2 (4%) 1.35 0.18–10.10 0.77
Relapsed Disease 2 (11%) 8 (14%) 0.78 0.18–3.36 0.74
ABVD=doxorubicin, bleomycin, vinblastine, dacarbazine, BEACOPP=bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, ESR= erythrocyte sedimentation rate.
∗
1 control from HD7 arm A (received RT only) excluded in this analysis.
Table 2
Standardized mortality ratio (SMR) stratiﬁed by age and sex in German Hodgkin Study Group (GHSG) cohort
Overall (male and female) Male patients Female Patients
Age
(years)
Observed
No. of
Suicides
Expected
No. of
Suicides SMR 95% CI
Observed
No. of
Suicides
Expected
No. of
Suicides SMR 95% CI
Observed
No. of
Suicides
Expected
No. of
Suicides SMR 95% CI
20–29 4 1.77 2.26 0.72–5.45 4 1.40 2.86 0.91–6.89 0 0.33 0 N/A
30–39 1 2.91 0.34 0.02–1.70 1 2.54 0.39 0.02–1.94 0 0.51 0 N/A
40–49 7 3.22 2.17 0.95–4.30 7 3.01 2.33 1.02–4.60 0 0.55 0 N/A
50–59 7 2.20 3.18 1.39–6.29 5 2.10 2.38 0.87–5.28 2 0.39 5.13 0.86–16.94
Total 19 11.67 1.63 1.01–2.50 17 10.45 1.63 0.98–2.55 2 2.11 0.95 0.16–3.13
A.I. Kim et al Suicide in European Hodgkin Lymphoma Patients
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Study Group (GHSG) HD7 through HD15 studies. The GHSG
HD7-HD15 studies accrued patients from Germany,
Switzerland, the Netherlands, the Czech Republic, and Austria
between 1993 and 2009 and were analyzed to identify those
patients with Hodgkin Lymphoma whose cause of death was
suicide. All causes of death in the HD7-HD15 studies were
reported to the GHSG by the patients’ treating physician. Death
by suicide was documented when the treating physician reported
suicide as the cause of death. The present study includes the ﬁnal
analyses of all 9 trials and the 10 and 15-year follow-up analyses
of the GHSGHD7-HD12 studies.We restricted the single-patient
analysis to include only suicides and survival data published in
manuscript or abstract form.2–14 All 9 GHSG HD7-HD15 trials
were approved by respective local institutional review boards.
Our validation cohort included all SEER patients with available
survival data diagnosed with HL between 1973 and 2013 (n=
52,115).15 This registry does not contain the same in-depth
clinical information as the GHSG data, but does contain age, date
of diagnosis, stage, survival data, and cause of death.
Cohort analysis
Primary endpoints of this analysis were the crude death rate and
SMR of death from suicide. SMRwas obtained by calculating the
ratio of observed number of suicides in the GHSG HL cohort to
the expected number of suicides in the general European
standardized population for 2014 taken from the statistical
ofﬁce of the European Union, Eurostat.16 Eurostat includes data
from 28 European countries (EU-28) to generate overall and sex-
speciﬁc mortality rates for all causes of death. Eurostat cause of
death data is derived from death certiﬁcates from all member
states that are coded based on ICD10 (International Statistical
Classiﬁcation of Diseases and Related Health Problems). ICD10
codes X60-X84 were included in the analysis for suicide
(intentional self-harm). To account for the age distribution of
the GHSG HL cohort, the sum of the observed person-years
within each age group (ages 15–19, 20–24, 25–29 . . . ., ≥85)
was used to calculate the expected number of suicides within each
age group, referencing the 2014 EU-28 crude suicide rates of each
age group. The SEER validation data was analyzed in the same
manner; however, the U.S. population was the reference for
which age- and sex-speciﬁc suicide data was obtained from the
Center for Disease Control and Prevention (CDC).17
Variables
Variables extracted from the GHSG HD7-HD15 trials included
sex and age at time of diagnosis and suicide, B symptoms,
elevated ESR, bulky mediastinal disease, ≥ 3 nodal areas,
relapsed disease, stage, radiation therapy, ABVD or BEACOPP-
based chemotherapy, and development of secondarymalignancies.
Case-control and statistical analyses
For each case of suicide, 3 controls matched for exact age were
selected from the sameGHSG trial. Thus, the 5-year time range at
enrollment (1993–1998, 1998–2003, or 2003–2008) and GHSG
HL risk stratiﬁcation group (early stage favorable, early stage
unfavorable, and advanced stage) were also matched. Case-
control approach was used to identify the variables above
associated with risk of death by suicide. The SEER validation
data was similarly analyzed, though only 1 control for each case
of suicide was matched for exact age and year of diagnosis, as 3
controls were not available for all cases.
Univariate and multivariate conditional logistic regression
analyses were performed to generate odds ratios (OR) and their
95% conﬁdence intervals (CI) for each of the variables listed to
identify factors associated with an increased risk of death by
suicide. Male sex, the presence of large mediastinal mass, and
stage (stage IV vs stage I-III) were selected for a multivariate
analysis as they were the variables in the univariate analyses with
OR furthest from 1. Other variables in the univariate analyses
were omitted from the multivariate analyses as there were not
enough cases of suicide to support their inclusion. Statistical
analyses were performed using SAS statistical software (version
9.4; SAS Institute Inc, Cary, NC). All p values are 2-sided with
type I error rate ﬁxed at 0.05.
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